29 results were returned
International law firm Bird & Bird has advised Korean-based Mirae Asset Capital, Celltrion and Premier Partners on Iksuda Therapeutics Limited’s (Iksuda) USD 47 million Series A financing (circa GBP 34 million).
Congratulations to our Life Sciences and Healthcare team who were recently presented with seven accolades at the LMG Life Sciences Europe Awards 2021, announced 13th May.
Bird & Bird has advised publicly traded Australian Elixinol Global Limited on the acquisition of leading German CBD company, CannaCare Health GmbH, Hamburg, by a Dutch subsidiary.
Our international Life Sciences & Healthcare Group is extremely proud to have been recognised among individuals and companies behind the most innovative and challenging Life Sciences work of the past year, as well as ...
International law firm Bird & Bird advised global safety equipment manufacturer MSA Safety Incorporated (NYSE: MSA) on the acquisition of U.K.-based Bristol Uniforms (“Bristol”) in an all-cash transaction valued at ...
Bird & Bird LLP has advised the US company InGeneron on the sale of 100% of the shares in the Munich-based private umbilical cord blood banking company Eticur GmbH to Polski Bank Komórek Macierzystych.
Bird & Bird represented ArchiMed, a European healthcare-focused private equity fund, in three simultaneous acquisitions that will create an innovative market leader in the bioanalytical market.
The Swedish listed company AddLife AB is a market leading player within Life Science offering quality products and advice to both the private and the public sectors, primarily in the Nordics and the rest of Europe.
Bird & Bird law firm advised Indian vaccine manufacturer Serum Institute of India Pvt. Ltd (part of Cyrus Poonawalla Group) on the sale of Czech unit, Praha Vaccines a.s., to Novavax AB, subsidiary of Novavax Inc, US ...
We add to the ink already spilled on the Commission’s controversial new Article 22 Referral Guidance that sets out the Commission’s game plan to claim jurisdiction over potential “killer acquisitions” even if no ...